Ribociclib (Kisqali)

Medicine at a glance

• Generic name: ribociclib; verified brand: Kisqali.
• Treatment type: a cyclin-dependent kinase 4 and 6 inhibitor, often shortened to CDK4/6 inhibitor.
• Form: 200 mg film-coated tablets, taken once daily on prescribed treatment days.
• Usual calendar: 21 days taking ribociclib followed by seven days without it, making a 28-day cycle.
• Important checks: blood counts, liver function, blood salts and an ECG, a recording of the heart's electrical activity.
• Accompanying treatment: an aromatase inhibitor or, in an appropriate treatment plan, fulvestrant. Tamoxifen should not be combined with ribociclib.

Kisqali Femara Co-Pack is a verified product containing separate ribociclib and letrozole tablets. It is not one tablet containing both medicines. The two tablet calendars differ. Brand information does not establish local availability.

What ribociclib is and how it works

Cells use proteins called CDK4 and CDK6 to move through the steps needed to divide. Ribociclib blocks these proteins, helping to slow the growth of cancer cells that depend on this pathway. It is a targeted treatment, rather than conventional chemotherapy or a checkpoint immunotherapy. Targeted treatment can still affect healthy cells and cause serious side effects.

Hormone treatment works alongside it by reducing oestrogen production or blocking oestrogen's effect. The medicines act at different points in the cancer's growth process. Taking ribociclib without the prescribed accompanying medicine is not an equivalent treatment plan. The intended benefit and treatment length depend on your circumstances; no medicine can guarantee that cancer will remain controlled.

How the team decides whether it is suitable

Your oncologist considers the diagnosis, previous treatment, risk of recurrence or current extent of disease, overall health and applicable prescribing information. A tumour sample is assessed for hormone receptors and HER2. Hormone receptor positive means the cancer has proteins through which hormones can encourage growth; HER2 negative describes a different tumour protein test. These results help the team decide whether this approach is appropriate.

Heart-rhythm problems, liver disease, kidney function and interacting medicines can influence the decision. Some risks need correction before the first tablet, while others may mean a different treatment is safer. The team also considers whether you can attend the required early appointments.

The plan includes hormone-suppressing injections for people who have not completed menopause and, according to the prescribed regimen, for men. These injections help the hormone treatment work as intended. Keep their appointments as well as taking the tablets. Ribociclib's safety and effectiveness in children have not been established.

Before treatment starts

Tell the team about previous fainting, an irregular or unusually slow heartbeat, heart disease, thyroid problems, uncontrolled blood pressure, liver or kidney problems, lung disease, current infection and previous severe drug reactions. Mention all allergies, including peanut or soya allergy. Kisqali contains soya lecithin; European information says people allergic to peanut or soya must not take it. Have the pharmacist check the exact supplied product before starting.

Bring a complete medicine list, including occasional antibiotics, anti-sickness medicines, sleeping tablets, supplements and herbal products. Interactions may change ribociclib levels or affect the heartbeat, even if the other medicine was previously safe for you.

Baseline checks usually include a complete blood count, liver tests, kidney function, potassium, calcium, magnesium and phosphate, and an ECG. Low or abnormal blood salts need correction. The ECG includes a measurement called QTcF; the prescribing information specifies a value below 450 milliseconds before starting. This is a clinician-interpreted safety measurement, not something to assess with a home pulse check. A pregnancy test is needed if you could become pregnant.

Before leaving, make sure you understand the tablet number, first treatment day, break days, laboratory appointments and how to obtain urgent advice outside clinic hours.

How ribociclib is taken

Dose and treatment calendar

Two standard starting examples are 400 mg daily, meaning two 200 mg tablets, in an early-treatment course, and 600 mg daily, meaning three tablets, in an advanced-disease course. Both usually follow 21 days on treatment and seven days off. The lower early-treatment starting dose is intentional. Your prescribed dose may be lower because of side effects, kidney or liver problems, or an unavoidable interaction. Never change tablet numbers yourself.

An early-treatment course is generally planned for three years, unless recurrence or unacceptable side effects require a change. In advanced disease, treatment generally continues while it is helping and side effects remain manageable. The hormone medicine may continue for a different length of time.

Use a dated calendar. Do not assume each cycle begins on the same calendar date every month, or restart after a delay without confirmation. Blood results may mean the next cycle starts later.

Food, swallowing and accompanying medicines

Take the daily ribociclib tablets together, at approximately the same time, preferably in the morning. Food is optional. Swallow tablets whole with water; do not chew, crush, split or dissolve them. Do not take damaged or broken tablets. If swallowing is difficult or you use a feeding tube, contact the pharmacist for a different plan rather than preparing a mixture yourself. Avoid grapefruit and grapefruit juice.

The seven-day break usually applies to ribociclib, not the accompanying hormone treatment. For example, the Kisqali Femara Co-Pack contains ribociclib for 21 days and one 2.5 mg letrozole tablet every day throughout the 28-day cycle. Follow each medicine's instructions separately. Fulvestrant follows an injection schedule.

Missed dose, vomiting and storage

If you miss a ribociclib dose, skip it for that day and take the next prescribed dose at its usual time. If you vomit after taking it, do not take replacement tablets that day. Never double a dose or add missed tablets to the break week. Record what happened; repeated vomiting or missed doses needs advice.

Keep tablets in their original packaging, protected from moisture and out of children's reach. US information specifies storage at 20–25°C (68–77°F); European information gives no special temperature condition. Follow your pack and avoid hot cars or damp bathrooms. Ask the pharmacy to arrange safe disposal of unused tablets. If you accidentally take too much, seek medical advice immediately and take the packaging with you.

Monitoring and checking whether treatment is working

Monitoring can find a problem before symptoms develop. Current US and European product information recommend:

• Complete blood count and liver tests before treatment, every two weeks during the first two cycles, at the beginning of each of the next four cycles, and subsequently as clinically needed.
• ECG before treatment and at approximately day 14 of the first cycle, with additional recordings when clinically needed.
• Blood salts before treatment and at the beginning of the first six cycles, with further checks according to results, symptoms and other medicines.

More frequent testing may be needed after an abnormal result. Your hospital may use additional checks; a normal first ECG does not remove the need for later monitoring. Vomiting or diarrhoea can disturb blood salts and increase heart-rhythm risk.

Kidney blood tests may also change. Ribociclib can affect the movement of creatinine, a substance measured in these tests, without necessarily reducing kidney filtration. The team must still investigate an increase and exclude genuine kidney trouble or dehydration; do not dismiss it yourself.

A low white-cell count, liver change or ECG finding may lead to a pause, lower dose or permanent stop. A delay is a safety decision, not proof that treatment has failed. Restart only when instructed.

Effectiveness is assessed using the checks appropriate to your situation, including symptoms, examination and scans when needed. In treatment intended to reduce recurrence risk, there may be no visible tumour to measure. Side effects, or their absence, do not reliably show how well the medicine is working.

Common side effects and practical management

Low blood counts and infection precautions

Ribociclib commonly lowers neutrophils, white blood cells that help fight infection. You may feel well despite a low count. Wash hands regularly, practise food hygiene and avoid close contact with people who are clearly unwell. Report a fever, shaking chills, sore throat, cough, burning urine or sudden deterioration promptly. Do not wait for the next blood test.

Low red cells can cause tiredness, paleness or breathlessness. Low platelets can cause bruising or bleeding. Report these symptoms; breathlessness should not automatically be blamed on anaemia because lung and heart problems also need assessment.

Nausea, bowel changes and appetite

Small meals and regular sips may help nausea. Use only anti-sickness medicines checked by the team, because some affect heart rhythm. Tell them if you cannot keep fluids down.

For loose stools, record frequency and follow the supplied diarrhoea plan. Seek same-day advice for persistent diarrhoea, reduced urine, dizziness, fever or blood in stools. Constipation also deserves attention, particularly with pain or vomiting. If eating becomes difficult, request dietitian support before significant weight loss occurs.

Fatigue, headaches and discomfort

Balance rest with manageable activity such as short walks. Persistent fatigue may need blood tests or review of sleep, nutrition and other medicines. Report new or worsening headaches and pain; check painkillers with the pharmacist. Sudden severe symptoms require urgent assessment rather than extra rest alone.

Mouth, skin and hair changes

Use a soft toothbrush and gentle mouth care. Report ulcers, especially if they interfere with drinking or occur with fever. Mild dryness or itching may improve with a bland moisturiser and products recommended by the team. New rashes still need reporting because serious reactions can begin with apparently ordinary skin changes.

Hair may thin. The degree varies, and accompanying treatments contribute. Ask about practical hair care or head coverings if needed. Hair changes do not measure treatment benefit.

Effects of accompanying hormone treatment

Hot flushes, vaginal dryness and joint discomfort may relate to the hormone medicine. Aromatase inhibitors can affect bone health, so ask whether a bone-density assessment or bone-protection plan is appropriate. These concerns deserve help even when they are not emergencies. Do not stop one component without discussing the whole treatment plan.

Important risks to understand

Heart-rhythm changes

Ribociclib can lengthen the QT interval, the time the heart takes to electrically reset between beats. A marked change can allow a dangerous rhythm. It may be silent on symptoms but visible on an ECG. Risk increases with certain medicines or abnormal blood salts. Report new fluttering, racing heartbeat, unexplained dizziness or feeling faint immediately. Collapse, chest pain or severe breathing difficulty needs emergency care.

Liver injury

Liver enzymes can rise without symptoms; occasionally more serious liver injury occurs. Seek prompt advice for yellow eyes or skin, dark urine, pain beneath the right ribs, unusual loss of appetite, marked tiredness or easy bruising. Regular tests remain essential even when you feel well. The team may hold treatment while investigating; do not restart leftover tablets yourself.

Lung inflammation

Ribociclib can cause inflammation within the lungs, called pneumonitis or interstitial lung disease. New or worsening cough, breathlessness or difficulty getting enough air needs immediate assessment. Infection and other causes can look similar. Do not take another dose while urgently obtaining advice about suspected drug-related lung inflammation. US guidance requires immediate interruption during assessment and permanent stopping for severe or recurrent symptomatic inflammation. European guidance also requires stopping for severe inflammation; any restart after a less severe episode needs an individual specialist decision.

Severe skin reactions

Potentially life-threatening reactions can cause a spreading painful rash, blisters, peeling skin, sores affecting the mouth, eyes or genitals, fever or facial swelling. These can include Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS, a drug reaction affecting skin and sometimes internal organs. Do not take another dose while urgently obtaining medical assessment for these warning signs. Confirmed severe reactions require permanent withdrawal and must not be tested by restarting at home.

Other medicines, supplements and vaccinations

Ribociclib is processed through a system called CYP3A. Strong inhibitors, such as certain antifungals, clarithromycin and ritonavir-containing medicines, can raise ribociclib levels. Strong inducers, including rifampicin, carbamazepine, phenytoin and St John's wort, can lower them. Strong inhibitors and strong inducers should be avoided; if an inhibitor is unavoidable, the oncologist may adjust ribociclib. Separating the doses by a few hours does not solve these enzyme interactions.

Ribociclib can also raise levels of other medicines. Some cholesterol medicines, sedatives, strong painkillers and transplant medicines need particular attention. Medicines affecting the QT interval, including certain antibiotics, anti-sickness drugs and heart-rhythm treatments, require careful checking. European information additionally highlights monitoring for some transporter-related interactions, including digoxin and metformin. European guidance also notes that moderate enzyme inducers may reduce effectiveness. This is not a complete list.

Tamoxifen should not be combined with ribociclib because of increased QT effects. Do not substitute it for the prescribed hormone partner. Ask the pharmacist before starting, stopping or changing any medicine, including a short course from another clinic. Avoid grapefruit products and unreviewed herbal remedies.

Discuss vaccines with the team. Live vaccines may be unsuitable when immunity is weakened. Non-live vaccines may be appropriate, but timing and protection depend on your blood counts and other treatments. Do not apply a fixed post-treatment vaccine interval without advice.

Everyday life during treatment

Many people continue some work, caring responsibilities and exercise, with adjustments around fatigue and early monitoring. Arrange flexibility for blood tests and possible treatment delays. Tell the team if side effects or the tablet routine are becoming difficult; practical support may prevent missed doses.

Do not drive or operate machinery if dizzy, faint, unusually tired or otherwise impaired. New faintness needs assessment, not simply a decision to stop driving. Keep hydrated unless you have a prescribed fluid restriction. Discuss alcohol, particularly with liver-test changes or nausea.

Tell dentists and other healthcare professionals about ribociclib. Blood counts, infection risk and interactions may affect procedures and prescriptions. Plan travel around monitoring and carry the original packaging, prescription details and enough medicine, with a plan for urgent care away from home. Do not extend a break to suit travel without agreement.

Sexual discomfort, body-image changes and worry about recurrence or progression can be hard to discuss. Your team can help with symptom relief, counselling and support for partners as well as patients.

Fertility, contraception, pregnancy and breastfeeding

Ribociclib can harm a developing baby. If you could become pregnant, pregnancy status must be checked before treatment and effective contraception used throughout treatment and for at least three weeks, or 21 days, after the final dose. Break weeks still count as treatment. Report a suspected pregnancy promptly.

European information gives double-barrier contraception as an example; the US label specifies an effective method with a pregnancy rate below 1%. Ask the team to choose a reliable method appropriate to hormone-sensitive disease and all medicines. Do not assume hormone-suppressing injections, absent periods or reduced fertility prevent pregnancy.

Human fertility effects are uncertain. Animal findings suggest ribociclib may affect male fertility. Discuss fertility preservation before starting if having children later matters to you. Current US and European ribociclib information does not specify a separate fixed male post-treatment contraception interval; partners still need an individual plan that accounts for accompanying medicines.

Do not breastfeed during ribociclib treatment or for at least three weeks after its final dose. Other treatments may require longer contraception or breastfeeding restrictions. Obtain an end date based on the complete regimen rather than using ribociclib's interval to shorten another medicine's precautions.

After treatment finishes

Continue agreed tests until treatment-related abnormalities have recovered or stabilised. Liver problems, low blood counts or symptoms do not necessarily end with the last tablet. Keep using urgent advice for new or worsening symptoms.

Check whether the hormone medicine continues and confirm its prescription separately. Complete the contraception and breastfeeding precautions for every component. Return unused ribociclib to the pharmacy; do not save tablets for a possible future restart. Ask for a clear follow-up plan and support with ongoing fatigue, sexual symptoms or anxiety.

Frequently asked questions